Results 81 to 90 of about 50,613 (304)

Adalimumab in Psoriatic Arthritis

The Journal of Rheumatology Supplement, 2012
Open prospective studies and randomized controlled trials (RCT) have shown the short-term efficacy of adalimumab (ADA) in psoriatic arthritis (PsA) and psoriasis. ADA effectively treated all varied musculoskeletal manifestations characteristic of PsA, including peripheral arthritis, spinal disease, enthesitis, and dactylitis.
SALVARANI, CARLO, Pipitone, Nicolò, Catanoso, Mariagrazia, Chiarolanza, Ilaria, Boiardi, Luigi, Caruso, Andrea, Pazzola, Giulia, Macchioni, Pierluigi, Di Lernia, Vito, Albertini, Giuseppe   +9 more
openaire   +4 more sources

Measuring the Impact: Magnetic Resonance Imaging Response of Sacroiliac Joints to Tumor Necrosis Factor Inhibitors in Youth With Axial Disease

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the timeline for resolution of sacroiliac joint (SIJ) inflammation, changes in structural lesions, and their correlation with patient‐reported outcomes (PROs) in youth with axial juvenile spondyloarthritis (axJSpA) initiating tumor necrosis factor inhibitor (TNFi).
Timothy G. Brandon, Rui Xiao, Daniel J. Lovell, Edward Oberle, Matthew L. Stoll, Nancy A. Chauvin, Michael L. Francavilla, Walter P. Maksymowych, Pamela F. Weiss   +8 more
wiley   +1 more source

Health professional views on the assessment and management of foot problems in people with psoriatic arthritis in Australia and New Zealand: a qualitative investigation

BMC Musculoskeletal Disorders, 2019
Background Active foot disease persists in a high proportion of people with psoriatic arthritis despite the availability of pharmacological and non-pharmacological interventions to modify the course of the disease.
Kate Carter, Steven Walmsley, Keith Rome, Deborah E. Turner   +3 more
doaj   +1 more source

Psoriatic arthritis: novel targets add to a therapeutic renaissance

, 2018
Psoriasis is the most common chronic autoinflammatory skin disease, affecting 2–3% of the world's population, of whom 10–30% have psoriatic arthritis.
Peter Nash, Nash, Peter
core   +1 more source

The role of HLA-Cw6 in psoriasis and psoriatic arthritis

, 2022
Psoriasis (Ps) is an inflammatory disease of complex etiology. The development and course of psoriasis are influenced by genetic, environmental and immunological factors [1, 2].
Owczarek, Witold, Witold Owczarek
core   +1 more source

Early Psoriatic Arthritis

The Journal of Rheumatology Supplement, 2009
Early detection of psoriatic arthritis (PsA) can effectively help in reducing the risk of joint damage and disability. Accordingly, the authors offer diagnostic insights in order to improve the approach to the patient's medical history, clinical examination, and the imaging modalities.
Scarpa R., Atteno M., Costa L., Peluso R., Iervolino S., Caso F., Del Puente A.   +6 more
openaire   +4 more sources

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source

COVID-19 in patients with psoriasis: A Latin American case series

JAAD International, 2021
Isabela Campo-Slebi, MD, María Fernanda Meza-Corso, MD, Paola Cárdenas, MD, Juan Raúl Castro-Ayarza, MD, Cesar González, MD, Carolina Cortés, MD, Manuel Franco, MD, Fernando Valenzuela, MD   +7 more
doaj   +1 more source

CLINICAL OUTCOME MEASURES OF PSORIASIS

Reumatismo, 2011
Several tools have been introduced in clinical trials to quantify the severity and the response to a given therapeutic regimen of both psoriasis and psoriatic arthritis. Each method present specific advantages and limitations.
E. Berardesca, C. Bonifati
doaj   +1 more source

Osteoporosis and Psoriatic Arthritis

The Journal of Rheumatology Supplement, 2012
Osteoporosis (OP) is a skeletal disorder characterized by compromised bone strength that predisposes to an increased risk of fracture. The prevalence of OP in the general population is very high as established in several studies, and OP represents one of the possible aspects of bone involvement in arthritis.
DEL PUENTE, ANTONIO, Esposito A, Parisi A, ATTENO, MARIANGELA, Montalbano S, Vitiello M, Esposito C, Bertolini N, Foglia F, COSTA, LUISA, SCARPA, RAFFAELE   +10 more
openaire   +3 more sources